The Food and Drug Administration denied an emergency use authorization for fluvoxamine as a SARS-CoV-2 antiviral.
Subscribe to:
Post Comments (Atom)
< + > Stop Waiting on Mandates: CMS Challenges Health IT to Act Now
“We’re the government and we’re here to help.” That’s a common punchline, but based on recent IT announcements from CMS, this line may turn ...
No comments:
Post a Comment